Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 21

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 21
---
)(11) of the Securities Act, and any commissions received by them and any profit realized on the resale of the shares underlying the Warrants sold by them while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As underwriters, the placement agents would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the placement agents acting as principals. Under these rules and regulations, the placement agents:

| • |     | may not engage in any stabilization activity in connection with our securities; and |

| • |     | may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our                       
 securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution. |

Electronic Distribution This prospectus supplement and the accompanying prospectus may be made available in electronic format on websites or through other online services maintained by the placement agents or by an affiliate of the placement agents. Other than this prospectus supplement and the accompanying prospectus, the information on the placement agents’ websites and any information contained in any other websites maintained by the placement agents is not part of this prospectus supplement and the accompanying prospectus or the registration statement of which this prospectus supplement and the accompanying prospectus form a part, has not been approved and/or endorsed by us or the placement agents, and should not be relied upon by investors. Other Information The foregoing does not purport to be a complete statement of the terms and conditions of the Placement Agency Agreement and the securities purchase agreement. A copy of the securities purchase agreement with the investors will be included as an exhibit to our Current Report on Form 8-Kto be filed with the SEC in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. See “Where You Can Find More Information.” Determination of Offering Price and Exercise Price The offering price of the securities we are offering, and the exercise price of the Warrants were negotiated between us and the investors in the offering based on the trading of our Common Stock prior to the offering, S-17

among other things. Other factors considered in determining the offering price of the securities we are offering, as well as the exercise price of the Warrants